Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
CELESTICA INC
High uncertainty: The valuation methods show significant disagreement (>100% spread). Treat the range as a rough guide rather than a precise estimate.
Bear Case (25th pct.)
-77.2% vs price
Base Case (Median)
-70.4% vs price
Bull Case (75th pct.)
-36.9% vs price
◇ = Current price | | Bear | Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $68.46 | -76.8% | High (40%) |
| PE Comparable | $275.41 | -6.8% | Medium (25%) |
| Growth Trajectory DCF | $565.66 | 91.4% | Medium (20%) |
| Graham Number | $66.08 | -77.6% | Low (10%) |
| EV/EBITDA | $97.40 | -67.0% | Medium (20%) |
| EV/FCF | $87.39 | -70.4% | Medium (20%) |
| Earnings Power Value | $39.53 | -86.6% | Medium (50%) |
Based on 7 out of 7 methods, CLS appears overvalued at the current price of $295.50. The base case fair value of $87.39 implies 70.4% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.